maximum doses vary by indication
Biosimilar development is the medium-term democratization opportunity Biocon Biologics, Samsung Bioepis, and other biosimilar developers are advancing semaglutide biosimilar programs that, upon patent expiry, could reduce drug costs by 70-85% and dramatically expand patient access in both developed markets with coverage barriers and developing markets with affordability constraints
Who Should Be Cautious or Avoid It Growth hormone peptides are generally not appropriate during pregnancy, for people with active or recent cancer (because growth signaling and cell growth are linked), or where there are certain pituitary or metabolic conditions
& Lindeke, A
How do you stop kidney disease from progressing
2.4 Outcome measures of safety Our study evaluated the safety of tirzepatide with regard to two major adverse events: pancreatic adverse events and the composite of gallbladder or biliary diseases, cholecystitis, cholelithiasis, and biliary diseases
